What MedGenome does

MedGenome Labs Ltd. is a Bangalore-headquartered genomics diagnostics company founded in 2013, operating South Asia's largest CAP-accredited multiomics laboratory in Bangalore, with additional CAP- and NABL-accredited cytogenetic testing sites in Mumbai and Delhi. The company offers a 1,300+-test portfolio spanning reproductive health (Claria NIPT, prenatal exome, carrier screening, PGT, KaryoSeq), rare inherited disorders (whole exome, trio exome, clinical exome, BabySecure newborn screening, neuro/cardio/endocrine genetics panels), oncology (liquid biopsy, hereditary cancer, comprehensive myeloid/lymphoid, TumorTrack), and infectious disease (respiratory panels, TB drug resistance, HIV genotyping, sepsis AMR). Underlying technology is Illumina-based next-generation sequencing combined with proprietary analytics — most notably the VarMiner AI tool for variant interpretation — supported by ~7PB annual sequencing capacity and 500,000+ exomes/genomes sequenced to date.

MedGenome operates a hybrid go-to-market combining direct-to-consumer access (website, toll-free 1800 296 9696, WhatsApp, walk-in labs, genetic counselling) with a B2B referral network of 8,000+ hospitals and 24,000+ clinicians, supplemented by a franchisee program reaching Tier 2/3 cities and international research services across 40 countries. Revenue is generated primarily through unit-priced genetic diagnostic tests (₹20,000–₹1 lakh) and project-based multiomics research services for pharmaceutical partners (e.g., the Servier India AML/Cholangiocarcinoma biomarker partnership and the Signios Bio pharma/biotech services arm).

The company is venture-backed (cumulative funding reported at $185.5M including a 2022 $50M round led by Novo Holdings and a 2025 $47.5M round), with recent strategic activity focused on becoming a multi-modality diagnostics platform — acquiring Prognosis Laboratories (2023), Green Cross Genetics (2025), Medcare Management Services / Medcare Diagnostics (2026), and Siddhi Diagnostics (2026) to integrate radiology, pathology, and genomics into a single diagnostic ecosystem. MedGenome Labs Ltd. is a Bangalore-headquartered genomics diagnostics company founded in 2013, operating South Asia's largest CAP-accredited multiomics laboratory in Bangalore, with additional CAP- and NABL-accredited cytogenetic testing sites in Mumbai and Delhi. The company offers a 1,300+-test portfolio spanning reproductive health (Claria NIPT, prenatal exome, carrier screening, PGT, KaryoSeq), rare inherited disorders (whole exome, trio exome, clinical exome, BabySecure newborn screening, neuro/cardio/endocrine genetics panels), oncology (liquid biopsy, hereditary cancer, comprehensive myeloid/lymphoid, TumorTrack), and infectious disease (respiratory panels, TB drug resistance, HIV genotyping, sepsis AMR). Underlying technology is Illumina-based next-generation sequencing combined with proprietary analytics — most notably the VarMiner AI tool for variant interpretation — supported by ~7PB annual sequencing capacity and 500,000+ exomes/genomes sequenced to date.

MedGenome operates a hybrid go-to-market combining direct-to-consumer access (website, toll-free 1800 296 9696, WhatsApp, walk-in labs, genetic counselling) with a B2B referral network of 8,000+ hospitals and 24,000+ clinicians, supplemented by a franchisee program reaching Tier 2/3 cities and international research services across 40 countries. Revenue is generated primarily through unit-priced genetic diagnostic tests (₹20,000–₹1 lakh) and project-based multiomics research services for pharmaceutical partners (e.g., the Servier India AML/Cholangiocarcinoma biomarker partnership and the Signios Bio pharma/biotech services arm).

The company is venture-backed (cumulative funding reported at $185.5M including a 2022 $50M round led by Novo Holdings and a 2025 $47.5M round), with recent strategic activity focused on becoming a multi-modality diagnostics platform — acquiring Prognosis Laboratories (2023), Green Cross Genetics (2025), Medcare Management Services / Medcare Diagnostics (2026), and Siddhi Diagnostics (2026) to integrate radiology, pathology, and genomics into a single diagnostic ecosystem.

Name

MedGenome

Legal name

MedGenome Labs Ltd.

Website

https://diagnostics.medgenome.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

501–1,000 employees

Short description

MedGenome is a Bangalore-based genomics diagnostics company operating South Asia's largest CAP-accredited multiomics laboratory, offering 1,300+ genetic tests across reproductive health, rare diseases, oncology, and infectious disease to 8,000+ hospitals and 24,000+ clinicians across India and 40 countries.

Ownership category

akta.pro rank

Product category

Genetic Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Genetic diagnostics
• Genomic testing services
• Reproductive health screening
• Oncology genomic profiling
• Multiomics research services

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Genetic Diagnostic Testing Services: MedGenome generates revenue through providing genetic diagnostic tests across reproductive health, rare inherited disorders, oncology, and infectious diseases. Tests include NIPT, exome sequencing, carrier screening, oncology panels, and newborn screening, offered as one-time tests with pricing ranging from ₹20,000 to ₹1 lakh depending on complexity.
2. Research Services for Pharma Partners: MedGenome provides multiomics research services to pharmaceutical companies, enabling precision medicine and drug discovery. This includes bioinformatics, genomic analysis, and multi-omics platform services through the company's research division.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels10 records

Core offering

MedGenome operates a CAP-accredited multiomics laboratory providing genetic diagnostic testing services across four verticals: reproductive health, rare inherited disorders, oncology, and infectious diseases. The portfolio spans over 1,300 diagnostic tests including Claria NIPT, exome sequencing (Whole/Clinical/ExomeMAX), KaryoSeq, carrier screening, newborn screening, liquid biopsy, hereditary cancer panels, and infectious disease molecular panels, supported by proprietary VarMiner AI for variant analysis. The company also delivers multi-omics research services to pharmaceutical and academic partners via its Signios Bio division.

Product overview

MedGenome is a multi-omics diagnostics company offering a comprehensive genetic testing portfolio through its CAP-accredited laboratory. The core offering includes Claria NIPT for prenatal screening, Prenatal Exome Sequencing (Clinical/Whole/ExomeMAX), Cytogenetic Testing, KaryoSeq low-pass WGS, and Carrier Screening panels (Silver/Gold/Platinum). The Rare Inherited Disorders portfolio features Whole Exome Sequencing, Clinical Exome Sequencing, Trio Exome Sequencing, BabySecure Newborn Screening, and Neuro Genetics panels. Oncology services include Liquid Biopsy, Hereditary Cancer Panel, and Comprehensive Myeloid/Lymphoid panels. Infectious Disease testing covers pathogen panels for respiratory, TB, HIV, and tropical fevers. The company also offers Maternal Serum Screening, Preimplantation Genetic Testing (PGT-A/M/SR), and Chromosomal Microarray Analysis. All services are supported by the proprietary VarMiner AI platform for variant analysis. MedGenome operates South Asia's largest CAP-accredited multiomics laboratory with over 1,300 diagnostic tests across various disease categories.

Differentiator

Problem solved

Functional benefit

Brands

• Claria NIPT: Non-Invasive Prenatal Testing/Screening solution clinically validated for the Indian population
• BabySecure
• ExomeMAX
• KaryoSeq
• TumorTrack Advance
• Liquid Biopsy Test
• VarMiner
• Genessense

Products and services

• Claria NIPT Non-Invasive Prenatal Testing/Screening clinically validated for the Indian population, detecting trisomy 21, 18, 13 and sex chromosome abnormalities using NGS technology with >99.9% sensitivity and specificity.
• Prenatal Exome Sequencing (Clinical/Whole/ExomeMAX) NGS-based prenatal exome sequencing testing examining protein-coding regions to identify genetic disorders in developing fetuses, offered in Clinical (7,000+ genes), Whole Exome (20,000+ genes), and ExomeMAX (20,000+ genes with mitochondrial) variants.
• Cytogenetic Testing Chromosomal analysis services including karyotyping, high-resolution banding, FISH, and chromosomal microarray for prenatal diagnosis, products of conception analysis, male fertility testing, and cancer cytogenetics, performed at CAP/NABL accredited labs.
• KaryoSeq (Low-Pass Whole Genome Sequencing) Low-pass whole genome sequencing test for detecting chromosomal abnormalities including aneuploidies and copy number variations, offering higher resolution and faster turnaround than traditional karyotyping with 100% concordance for variants >50KB.
• Carrier Screening Panels (Silver / Gold / Platinum) Genetic carrier screening panels in Silver (100 genes), Gold (500 genes), and Platinum (~2000 genes) tiers using NGS and MLPA to identify carriers of autosomal recessive and X-linked recessive disorders for informed family planning.
• Maternal Serum Screening Prenatal blood screening tests for first and second trimester, including First Trimester Screening (β-hCG, PAPP-A), Quadruple Screening (AFP, β-hCG, uE3, Inhibin A), and pre-eclampsia risk assessment using DELFIA technology certified by FMF.
• Preimplantation Genetic Testing (PGT-A / PGT-M / PGT-SR) NGS-based embryo screening for IVF including PGT-A (aneuploidy), PGT-M (monogenic disorders), and PGT-SR (structural rearrangements), detecting chromosomal abnormalities with 100% sensitivity and 99.98% specificity.
• Chromosomal Microarray Analysis High-resolution genome analysis using CytoScan Optima, 750K, and KaryoTrack arrays, detecting submicroscopic CNVs, aneuploidies, triploidy, mosaicism, regions of homozygosity, and uniparental disomy with resolution down to 25kb.
• Whole Exome Sequencing (WES) / ExomeMAX Comprehensive sequencing of protein-coding regions covering 20,000+ genes at >80-100x depth, detecting SNVs, InDels, and CNVs, available as standard Whole Exome Sequencing and ExomeMAX (with mitochondrial gene coverage).
• Clinical Exome Sequencing Focused sequencing of 7,000+ disease-associated genes curated from OMIM, HGMD, and ClinVar databases, with improved CNV detection and phenotype-based analysis using the proprietary VarMiner tool.
• Trio Exome Sequencing Family-based exome sequencing analyzing child and both parents to identify inherited and de novo variants, enabling detection of autosomal dominant, recessive, and X-linked disorders with enhanced accuracy through Mendelian QC assessment.
• BabySecure Newborn Screening Newborn metabolic and genetic screening using Tandem Mass Spectrometry and GCMS, screening for 55–65+ disorders including fatty acid oxidation disorders, organic acid disorders, amino acid disorders, hemoglobinopathies, and congenital conditions.
• Neuro Genetics Panel Comprehensive neurology gene panel testing for genetic neurological disorders including epileptic disorders, neurocutaneous disorders, neuromuscular disorders, neurodegenerative disorders, neurometabolic disorders, movement disorders, and mitochondrial disorders.
• Liquid Biopsy Test Non-invasive cancer testing using circulating tumor DNA analysis for diagnosis and monitoring of hematological malignancies and solid tumors, enabling personalized treatment decisions without invasive tissue biopsy.
• Hereditary Cancer Panel Genetic testing panel for identifying inherited cancer risk mutations, screening for predisposition genes across multiple cancer types to enable early detection and preventive care strategies.
• Infectious Disease Molecular Panels Molecular diagnostic panels for infectious diseases including Respiratory Pathogen Panel, Tropical Fever Panel, TB Drug Resistance (SPIT SEQ), HIV Genotyping, CMV Drug Resistance, Sepsis AMR Panel, and comprehensive transplant infection testing.
• Multi-Omics Research Services (Signios Bio) Multi-omics research services delivered through Signios Bio (launched April 2025 as the rebranded US research division), offering AI-driven bioinformatics and advanced multi-omics platform services for precision medicine and drug discovery to pharma, biotech, and academic partners.

Quantifiable outcome

• 99.9% sensitivity and specificity for NIPT/NIPS testing
• +5 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• Athletics Federation of India (AFI)minorStrategic or Co-development Partner · 16 June 2026AFI mandated SRY gene testing for female athletes in domestic competitions, with tests conducted exclusively at MedGenome Labs Ltd. The federation bears the cost and began testing at the Federation meet in Ranchi, with the new requirement becoming mandatory from next year.
• Medcare Management ServicescoreStrategic or Co-development Partner · 2 March 2026MedGenome made a majority investment in Medcare Management Services, a Mumbai-based radiology and nuclear medicine provider founded in 2012. The partnership integrates Medcare's four imaging facilities and network of over 50 hospital partnerships with MedGenome's multi-omics capabilities to create a unified diagnostics ecosystem combining imaging, pathology, and genomics services.
• Servier IndiacoreStrategic or Co-development Partner · 11 November 2025Servier India partnered with MedGenome and Strand Life Sciences to provide subsidized cancer biomarker testing in India. The initiative offers affordable tests for Acute Myeloid Leukaemia (AML) and Cholangiocarcinoma (CCA) across India. Private sector costs are significantly reduced, and government sector tests are offered for free, including free IDH1 and IDH2 mutation tests for the government sector.
• Strand Life SciencescoreStrategic or Co-development Partner · 11 November 2025Partnered with Servier India and MedGenome for the biomarker testing initiative for AML and Cholangiocarcinoma, combining expertise in genomic testing to improve access to molecular diagnostics.
• Green Cross Genetics LabminorStrategic or Co-development Partner · 4 November 2025MedGenome announced a majority investment in Green Cross Genetics Lab to expand its diagnostics and genomics services in India. The partnership aims to enhance diagnostic infrastructure and accessibility, especially in Tier 2 and Tier 3 cities, leveraging Green Cross's extensive network and MedGenome's genomics expertise.
• Wodehouse CapitalminorImplementation/ SI/ Consulting Partner · 27 May 2023Transaction advisor for MedGenome's acquisition of Prognosis Laboratories, providing M&A advisory services for the deal.
• Khaitan & Co.minorImplementation/ SI/ Consulting Partner · 27 May 2023Legal advisor for MedGenome's acquisition of Prognosis Laboratories, providing legal counsel for the transaction.
• Prognosis LaboratoriescoreStrategic or Co-development Partner · 26 May 2023MedGenome Inc., backed by Sequoia Capital, acquired a controlling stake in Delhi-based Prognosis Laboratories, a diagnostics provider with multiple branches across India. The acquisition aims to expand MedGenome's network and accelerate growth in the diagnostics sector. Prognosis specializes in diagnostics, microbiology, and radiology with over 700 tests and multiple certifications.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Strand Life Sciences: India-based bioinformatics and clinical diagnostics company offering genomic testing and cancer biomarker services. Directly comparable as Strand partners with MedGenome on the Servier India AML/CCA biomarker initiative and competes in the same Indian genomics testing market.
• Mapmygenome: India-based consumer genomics company offering preventive health, ancestry, and clinical genetic tests. Comparable as a direct competitor in the Indian direct-to-consumer and clinician-referred genetic testing space.
• Natera: US-based genetic testing company specializing in reproductive health (NIPT, PGT), oncology (Signatera MRD), and organ transplant. Comparable business model with NGS-based tests sold through hospital and clinician networks.
• Invitae: US-based medical genetics company offering a broad menu of genetic tests across reproductive, oncology, and rare disease. Comparable in test menu breadth and clinician-channel distribution model.
• Color Genomics: US-based population genomics and genetic testing company offering hereditary cancer, pharmacogenomics, and whole genome sequencing. Comparable in clinician-channel distribution and hereditary cancer panel offerings.

Broad incumbents

• Myriad Genetics: Established US molecular diagnostics leader with strong positions in hereditary cancer (BRACAnalysis) and prenatal screening. Comparable in oncology and reproductive genetics test categories, but operates at much larger global scale.
• NeoGenomics: US-based oncology-focused clinical laboratory services company. Comparable in oncology genomics services including liquid biopsy and tumor profiling, though much larger and globally diversified.
• 23andMe: US-based consumer genetics leader with a large direct-to-consumer DNA testing platform. Comparable in DTC genetic testing motion and consumer genomics brand-building, though 23andMe focuses on ancestry and wellness rather than clinical diagnostics.

Regional players

• Dr. Lal PathLabs: India's largest diagnostic chain with extensive hospital and consumer reach across India. Comparable as a channel competitor for hospital referrals and consumer diagnostic spend, though MedGenome differentiates on genomics depth.

Emerging players

• 4baseCare: India-based precision oncology company focused on molecular profiling and targeted therapy selection. Comparable as an emerging Indian genomics player in oncology with overlapping cancer panel offerings.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/MedGenomeLabs
• YouTubeyoutube.com/@MedGenomeLabs
• Facebookfacebook.com/MedGenomeLabs
• LinkedInlinkedin.com/company/medgenomelabs
• Instagraminstagram.com/medgenome

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds9 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MedGenome